1
|
Abratenko P, Aduszkiewicz A, Akbar F, Pons MA, Asaadi J, Aslin M, Babicz M, Badgett WF, Bagby LF, Baibussinov B, Behera B, Bellini V, Beltramello O, Benocci R, Berger J, Berkman S, Bertolucci S, Bertoni R, Betancourt M, Bettini M, Biagi S, Biery K, Bitter O, Bonesini M, Boone T, Bottino B, Braggiotti A, Brailsford D, Bremer J, Brice SJ, Brio V, Brizzolari C, Brown J, Budd HS, Calaon F, Campani A, Carber D, Carneiro M, Terrazas IC, Carranza H, Casazza D, Castellani L, Castro A, Centro S, Cerati G, Chalifour M, Chambouvet P, Chatterjee A, Cherdack D, Cherubini S, Chithirasreemadam N, Cicerchia M, Cicero V, Coan T, Cocco AG, Convery MR, Copello S, Cristaldo E, Dange AA, de Icaza Astiz I, De Roeck A, Di Domizio S, Di Noto L, Di Stefano C, Di Ferdinando D, Diwan M, Dolan S, Domine L, Donati S, Doubnik R, Drielsma F, Dyer J, Dytman S, Fabre C, Fabris F, Falcone A, Farnese C, Fava A, Ferguson H, Ferrari A, Ferraro F, Gallice N, Garcia FG, Geynisman M, Giarin M, Gibin D, Gigli SG, Gioiosa A, Gu W, Guerzoni M, Guglielmi A, Gurung G, Hahn S, Hardin K, Hausner H, Heggestuen A, Hilgenberg C, Hogan M, Howard B, Howell R, Hrivnak J, Iliescu M, Ingratta G, James C, Jang W, Jung M, Jwa YJ, Kashur L, Ketchum W, Kim JS, Koh DH, Kose U, Larkin J, Laurenti G, Lukhanin G, Marchini S, Marshall CM, Martynenko S, Mauri N, Mazzacane A, McFarland KS, Méndez DP, Menegolli A, Meng G, Miranda OG, Mladenov D, Mogan A, Moggi N, Montagna E, Montanari C, Montanari A, Mooney M, Moreno-Granados G, Mueller J, Naples D, Nebot-Guinot M, Nessi M, Nichols T, Nicoletto M, Norris B, Palestini S, Pallavicini M, Paolone V, Papaleo R, Pasqualini L, Patrizii L, Peghin R, Petrillo G, Petta C, Pia V, Pietropaolo F, Poirot J, Poppi F, Pozzato M, Prata MC, Prosser A, Putnam G, Qian X, Rampazzo G, Rappoldi A, Raselli GL, Rechenmacher R, Resnati F, Ricci AM, Riccobene G, Rice L, Richards E, Rigamonti A, Rosenberg M, Rossella M, Rubbia C, Sala P, Sapienza P, Savage G, Scaramelli A, Scarpelli A, Schmitz D, Schukraft A, Sergiampietri F, Sirri G, Smedley JS, Soha AK, Spanu M, Stanco L, Stewart J, Suarez NB, Sutera C, Tanaka HA, Tenti M, Terao K, Terranova F, Togo V, Torretta D, Torti M, Tortorici F, Tosi N, Tsai YT, Tufanli S, Turcato M, Usher T, Varanini F, Ventura S, Vercellati F, Vicenzi M, Vignoli C, Viren B, Warner D, Williams Z, Wilson RJ, Wilson P, Wolfs J, Wongjirad T, Wood A, Worcester E, Worcester M, Wospakrik M, Yu H, Yu J, Zani A, Zatti PG, Zennamo J, Zettlemoyer JC, Zhang C, Zucchelli S, Zuckerbrot M. ICARUS at the Fermilab Short-Baseline Neutrino program: initial operation. THE EUROPEAN PHYSICAL JOURNAL. C, PARTICLES AND FIELDS 2023; 83:467. [PMID: 37303462 PMCID: PMC10239613 DOI: 10.1140/epjc/s10052-023-11610-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Accepted: 05/12/2023] [Indexed: 06/13/2023]
Abstract
The ICARUS collaboration employed the 760-ton T600 detector in a successful 3-year physics run at the underground LNGS laboratory, performing a sensitive search for LSND-like anomalous ν e appearance in the CERN Neutrino to Gran Sasso beam, which contributed to the constraints on the allowed neutrino oscillation parameters to a narrow region around 1 eV2 . After a significant overhaul at CERN, the T600 detector has been installed at Fermilab. In 2020 the cryogenic commissioning began with detector cool down, liquid argon filling and recirculation. ICARUS then started its operations collecting the first neutrino events from the booster neutrino beam (BNB) and the Neutrinos at the Main Injector (NuMI) beam off-axis, which were used to test the ICARUS event selection, reconstruction and analysis algorithms. ICARUS successfully completed its commissioning phase in June 2022. The first goal of the ICARUS data taking will be a study to either confirm or refute the claim by Neutrino-4 short-baseline reactor experiment. ICARUS will also perform measurement of neutrino cross sections with the NuMI beam and several Beyond Standard Model searches. After the first year of operations, ICARUS will search for evidence of sterile neutrinos jointly with the Short-Baseline Near Detector, within the Short-Baseline Neutrino program. In this paper, the main activities carried out during the overhauling and installation phases are highlighted. Preliminary technical results from the ICARUS commissioning data with the BNB and NuMI beams are presented both in terms of performance of all ICARUS subsystems and of capability to select and reconstruct neutrino events.
Collapse
|
2
|
Borrello A, Agnes A, Panunzi S, Piergentili I, Rossetto O, Fabris F, Magalini S, Gui D. Botulinum toxin infusion into the mesenteric artery has selective action on peristalsis in a rat model: experimental research. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2023; 27:3171-3180. [PMID: 37070920 DOI: 10.26355/eurrev_202304_31951] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 04/19/2023]
Abstract
OBJECTIVE Botulinum toxin type A (BoNT/A) reversibly blocks neurotransmission at voluntary and autonomic cholinergic nerve terminals, inducing paralysis. The aim of this study was to block panenteric peristalsis in rats through BoNT/A administration into the superior mesenteric artery (SMA) and to understand whether the toxin's action is selectively restricted to the perfused territory. MATERIALS AND METHODS Rats were infused through a 0.25-mm surgically inserted SMA catheter with different doses of BoNT/A (10 U, 20 U, 40 U BOTOX®, Allergan Inc.) or with saline for 24 h. Animals were free to move on an unrestricted diet. As a sign of bowel peristalsis impairment, body weight and oral/water intake were collected for 15 days. Statistical analysis was conducted with nonlinear mixed effects models to study the variation over time of the response variables. In three 40 U-treated rats, the selectivity of the intra-arterial delivered toxin action was studied by examining bowel and voluntary muscle samples and checking the presence of BoNT/A-cleaved SNAP-25 (the smoking gun of the toxin action) using the Immunofluorescence (IF) method through a specific antibody recognition. RESULTS While control rats exhibited an increasing body weight, treated rats showed an initial dose-dependent weight reduction (p<0.001 control vs. treated) with recovery after Day 11 for 10 and 20 U-treated rats. Food and water intake over time showed significantly different half-saturation constants with rats treated with higher doses who reached half of the maximum achievable in a greater number of days (p<0.0001 control vs. treated rats). BoNT/A-cleaved SNAP-25 was identified in bowel wall NMJs and not in voluntary muscles, demonstrating the remarkable selectivity of arterially infused BoNT/A. CONCLUSIONS Blockade of intestinal peristalsis, can be induced in rats by slow infusion of BoNT/A into the SMA. The effect is long-lasting, dose-dependent and selective. BoNT/A delivery into the SMA through a percutaneous catheter could prove clinically useful in the treatment of entero-atmospheric fistula by temporarily reducing fistula output.
Collapse
|
3
|
Casula M, Fortuni F, Frassica R, Coccia M, Magrini G, Fabris F, Gnecchi M, Leonardi S, Savastano S, Rordorf R. D-dimer for the prediction of left atrial appendage thrombosis: daydream or reality? A meta-analysis. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Left atrial appendage thrombosis (LAAT) is a dangerous condition that mainly affects patients with atrial fibrillation (AF) or those with mitral stenosis (MS), increasing their risk of stroke. Transesophageal echocardiography (TEE) is the gold standard for the diagnosis of LAAT but some technical issues and the suboptimal sensitivity in identifying small thrombi, especially within a side lobe, can limit its clinical usefulness. Reliable non-invasive diagnostic methods could be useful in clinical practice. D-dimer, a fibrin degradation product already commonly used in the diagnostic work-up of conditions such as venous thromboembolism, may have a role as a non-invasive marker of LAAT.
Purpose
To evaluate the diagnostic performance of D-dimer for the detection of LAAT in patients with AF and/or MS, using TEE as the reference standard.
Methods
We searched the literature for studies that evaluated the ability of D-dimer to predict LAAT. For each study a 2x2 table of D-dimer positivity and LAAT presence was constructed. Sensitivity, specificity, positive predictive value and negative predictive value were calculated. Considering the different diagnostic thresholds used in the included studies, the overall sensitivity and specificity were calculated using a hierarchal summary receiver operating characteristic (HSROC) model and a SROC curve was generated.
Results
6 studies, evaluating 1380 patients of whom 154 had LAAT, were included in the analysis. The prevalence of LAAT in the studies ranged from 9% to 26%, with a median of 12%. The mean age was 60±13 years, 63% were male. The mean left atrial diameter was 43±3 mm. The D-dimer diagnostic threshold ranged from 200 mcg/l to 1150 mcg/l. The overall sensitivity calculated with the HSROC model was 85%±28% and the overall specificity was 82%±29%. The negative predictive value was 98%. Figure 1 shows the summary ROC curve: individual studies are depicted by a clear circle; the red circle marks the pooled sensitivity and specificity across the 6 studies. The red dot-dashed-curve marks the boundary of the 95% credible region for the pooled estimates of sensitivity and specificity.
Conclusions
Our analysis shows that D-dimer has a good diagnostic performance with a very high negative predictive value for LAAT and therefore it might be of clinical aid for ruling out the presence of LAAT in patients with AF and/or MS. Further studies are needed to determine the best diagnostic threshold.
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
|
4
|
Casula M, Fortuni F, Fabris F, Leonardi S, Gnecchi M, Greco A, Sanzo A, Rordorf R. P569Efficacy and safety of direct Xa oral inhibitors versus warfarin in patients with atrial fibrillation and cancer: a meta-analysis of randomized controlled trials. Europace 2020. [DOI: 10.1093/europace/euaa162.244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Patients with cancer are at higher risk of atrial fibrillation (AF) compared with the general population. Furthermore, cancer per se and anti-cancer treatments have been associated with thromboembolic complications and increased bleeding risk. Considering that only 12% of cancer patients can achieve a stable International Normalized Ratio target and the frequent need for invasive procedures, warfarin is not an ideal option. Direct oral anticoagulants may theoretically represent a valid alternative although their use in this population has been scarcely investigated.
Purpose
To compare efficacy and safety of direct oral Xa inhibitors (DOXaI) versus warfarin in patients with atrial fibrillation and cancer.
Methods
We searched electronic databases for randomized controlled trials (RCTs) that analyzed the use of DOXaI versus warfarin in patients with AF and cancer. The primary efficacy outcome was stroke or systemic embolism (SE). The secondary efficacy outcomes were ischemic stroke, myocardial infarction and all-cause death. The primary safety outcome was major bleeding; secondary safety outcomes were major or clinically relevant non-major bleeding, intracranial bleeding and any bleeding. The net clinical benefit was estimated as the composite of the two primary outcomes. A sensitivity analysis was performed to better define the incidence of these outcomes in patients with active cancer. The statistical software ProMeta 3 was used to estimate the risk ratio with a random-effect model.
Results
3 RCTs counting a total of 3029 cancer patients (1682 on DOXaI and 1347 on warfarin), 1354 of whom with active cancer (856 on DOXaI and 502 on warfarin), were included in the analysis. Mean age was 75.6 ± 1.2 years, and 32% were female. Mean follow-up period was 2.2 ± 0.6 years. The most common cancer sites were prostate (23%), gastrointestinal tract (22.2%), breast (12.1%) and genitourinary tract (10.6%). The mean CHADS2 score was 2.9 ± 0.6 and the mean HAS-BLED score was 2.6 ± 0.4.
There were no significant differences in the risk of stroke or SE (RR 0.76; 95% CI 0.52-1.10) as well as for all the other secondary efficacy outcomes. DOXaI significantly reduced the incidence of major bleeding in the overall cancer population (RR 0.79; 95% CI 0.63-0.99; p = 0.039); this finding was consistent also in patients with active cancer (RR 0.79; 95% CI 0.59-1.05) although the effect was not statistically significant. DOXaI also significantly reduced intracranial bleeding in overall cancer population (RR 0.12; 95% CI 0.02-0.63; p = 0.013) and any bleeding in active cancer patients (RR 0.87; 95% CI 0.77-0.98; p = 0.026). Furthermore, DOXaI significantly reduced the composite endpoints of major bleeding and stroke or SE in overall cancer population (RR 0.78; 95% CI 0.64-0.94; p = 0.008).
Conclusions
Our metanalysis shows that, in patients with atrial fibrillation and cancer, DOXaI are safer and have a similar efficacy compared with warfarin.
Abstract Figure. Primary efficacy and safety outcomes
Collapse
|
5
|
Camporese G, Bernardi D, Bernardi E, Avruscio GP, Marchini F, Bonfante L, Furian L, Neri F, Villalta S, Fabris F, Simioni P, Sartori MT. Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. Vascul Pharmacol 2020; 130:106682. [PMID: 32438078 DOI: 10.1016/j.vph.2020.106682] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2019] [Revised: 02/24/2020] [Accepted: 05/08/2020] [Indexed: 01/03/2023]
Abstract
No data are available on rivaroxaban use in renal transplant recipients and on its surmised interaction with immunosuppressants. The aim was to investigate potential interactions between rivaroxaban and immunosuppressants in this setting. Renal transplant recipients with a stable renal function treated with rivaroxaban and tacrolimus with or without everolimus were investigated. All drugs and creatinine concentrations were determined daily for 2 weeks after the start of anticoagulation. Blood samples were drawn at 8.00 am and 3-4 h later for trough and peak concentrations, respectively. Bleeding and thrombotic events were recorded during a minimum follow-up of 6 months. In 8 renal transplant patients, rivaroxaban levels showed a predictable pharmacokinetic trend, both at Ctrough (30-61 μg/L) and at Cpeak (143-449 μg/L), with limited variability in the 25th-75th percentile range. Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well. Immunosuppressors variability before and after rivaroxaban were 30% and 30% for tacrolimus, 27% and 29% for everolimus, respectively, as well as 14% and 3% for creatinine. For rivaroxaban monitoring, the reference change value better performed in identifying significant variations of its concentration. No patient had bleeding or thrombotic events, worsening of renal graft function, and signs of immunosuppressants toxicity during a mean follow-up of 23 (9-28) months. In conclusion, rivaroxaban does not seem to interact with tacrolimus and everolimus in renal transplant recipients. Both anticoagulant and immunosuppressive effects seem warranted, without major bleeding complications and effect on the graft function.
Collapse
|
6
|
Rossetto O, Pirazzini M, Fabris F, Montecucco C. Botulinum Neurotoxins: Mechanism of Action. Handb Exp Pharmacol 2020; 263:35-47. [PMID: 32277300 DOI: 10.1007/164_2020_355] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Botulinum neurotoxins (BoNTs) are a growing family of bacterial protein toxins that cause botulism, a rare but often fatal animal and human disease. They are the most potent toxins known owing to their molecular architecture, which underlies their mechanism of action. BoNTs target peripheral nerve terminals by a unique mode of binding and enter into their cytosol where they cleave SNARE proteins, thus inhibiting the neurotransmitter release. The specificity and rapidity of binding, which limits the anatomical area of its neuroparalytic action, and its reversible action make BoNT a valuable pharmaceutical to treat neurological and non-neurological diseases determined by hyperactivity of cholinergic nerve terminals. This review reports the progress on our understanding of how BoNTs cause nerve paralysis highlighting the different steps of their molecular mechanism of action as key aspects to explain their extreme toxicity but also their unique pharmacological properties.
Collapse
|
7
|
Mascarenhas J, Marcellino BK, Lu M, Kremyanskaya M, Fabris F, Sandy L, Mehrotra M, Houldsworth J, Najfeld V, El Jamal S, Petersen B, Moshier E, Hoffman R. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF). Leuk Res 2019; 88:106272. [PMID: 31778911 DOI: 10.1016/j.leukres.2019.106272] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2019] [Revised: 11/12/2019] [Accepted: 11/13/2019] [Indexed: 01/23/2023]
Abstract
Ruxolitinib, a selective JAK1/JAK2 inhibitor, is the current first line therapy for myelofibrosis (MF), which reduces symptomatology and splenomegaly, but does not clearly modify disease course. Panobinostat, a histone deacetylase inhibitor, was shown to be safe and tolerable in phase I and II trials and demonstrated clinical activity in approximately a third of treated patients. Combination therapy of ruxolitinib and panobinostat showed synergistic activity in a preclinical MF model, which prompted clinical evaluation of this combination in both ruxolitinib naïve and treated MF patients. Herein, we report the results of an investigator-initiated, dose escalation, phase I trial of ruxolitinib and panobinostat in 15 patients with primary MF and post-polycythemia vera/essential thrombocythemia MF. This combination treatment proved to be safe and tolerable without dose limiting thrombocytopenia and a maximum tolerated dose of both agents in combination was not determined. The majority of patients maintained stable disease with this combination treatment and 40 % attained a clinical improvement (spleen n = 5, anemia n = 1) by modified IWG-MRT at the end of 6 cycles. This is one of the first attempts of rationally designed, JAK inhibitor-based, combination therapy studies and exemplifies the feasibility of such an approach in patients with advanced MF.
Collapse
|
8
|
Scarinzi P, Bigolin P, Simoni F, Benvegnù L, Antonucci A, Biolo M, Panzavolta C, Bertocco S, Zambon S, Fabris F, Manzato E, Previato L, Zambon A. Ultrasonographic detection of xanthomas in achilles tendon of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Prosdocimi M, Scattolo N, Zatta A, Fabris F, Stevanato F, Girolami A, Cella G. Clearance and In Vivo Release by Heparin of Human Platelet Factor 4 (PF4) in the Rabbit. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1661162] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
Summary13 male New Zealand rabbits were injected with two different doses (25 μg/Kg and 100 μg/Kg) of human platelet factor 4 antigen (PF4). The disappearance of the protein was extremely fast with an half-life for the fast component of 1.07 ± 0.16 and 1.76 ± 0.11 min respectively. The half-life for the slow component, detectable only with the highest dosage, was 18.8 min.The administration of 2500 I.U. of heparin 30 min after PF4 administration induced a partial release of the injected protein and its clearance from plasma was slow, with half-life of 23.3 ± 5.9 min and 30.9 ± 2.19 min respectively.
Collapse
|
10
|
Fabris F, Randi M, Casonato A, Luzzato G, Mazzucato M, Girolami A. The Significance of Plasma and/or Platelet Activated Products After Apheresis Procedures. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1665268] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
11
|
Zanon RDB, Fornasiero L, Boscaro M, Cappellato G, Fabris F, Girolami A. Increased Factor VIII Associated Activities in Cushing's Syndrome: A Probable Hypercoagulable State. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1657142] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThirteen women and 2 men affected by Cushing’s syndrome were investigated. The following parameters were used: plasma and urinary cortisol levels, factor VIII assay (antigen, activity and von Willebrand factor) together with other coagulative assays.Samples were taken before surgery or before medical and/or radiation therapy and every 30–50 days after treatment and continued for 11 months. Cortisol and factor VIII were increased before treatment and decreased slowly after treatment to become normal in 3–4 months. Other clotting tests did not show significant changes. It seems that high plasma cortisol levels may stimulate the production of factor VIII. Patients with Cushing’s syndrome often exhibit thromboembolic complications after surgery. It is likely that the clotting abnormalities responsible for such complications is the increased factor VIII activities level.
Collapse
|
12
|
Fabris F, Randi M, Casonato A, Scattolo N, Girolami A. Platelet Serotonin and Platelet Aggregation in the Differential Diagnosis of Thrombocytosis. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1657298] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
13
|
Randi ML, Fabris F, Casonato A, Girolami A. The Effect of Anticoagulant Mixtures on BTG and PF4 levels. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1653415] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
14
|
Abstract
ZusammenfassungDie kongenitalen und erworbenen Faktor-VII-Mangelzustände und Varianten sind jetzt gut bekannte klinische Einheiten. Der kongenitale Faktor-VII-Mangel ist eine autosomal inkomplett rezessiv vererbte Erkrankung. Er ist charakterisiert durch den Mangel an Faktor-VII-Aktivität und Faktor-VII-Antigen (echter Mangel) oder durch den Mangel an Aktivität und verschiedene Mengen von Antigen (Variante oder abnorme Formen). Außerdem zeigen einige Patienten mit normalem Faktor-VII-Antigen eine unterschiedliche Reaktivität mit verschiedenen Gewebethrombo-plastinen. Faktor VII Padua z.B. zeigt eine normale Reaktivität mit Ochsenhirn-Thromboplastin und eine niedrige Aktivität mit Kaninchenhirn-Thromboplastin. Die Klassifizierung des kongenitalen Faktor-VII-Defektes muß daher beide Fakten berücksichtigen, nämlich das Fehlen oder die Gegenwart von Antigen (VII_, VIIred und VII+) und die Reaktivität mit Gewebethromboplastin verschiedener Herkunft. Die Blutungsmanifestationen sind variabel und nicht spezifisch. In schweren Fällen sind Hämarthro-sen beschrieben worden. Bei manchen Patienten ist die Blutungsneigung mild. Gelegentlich sind auch thrombo-embolische Manifestationen beschrieben worden, was bedeutet, daß ein Mangel an Faktor VII kein Schutz gegen thrombotische Phänomene ist. Die Diagnose des Faktor-VII-Defekts basiert auf dem Nachweis einer verlängerten Prothrombinzeit gemeinsam mit einer normalen partiellen Throm-boplastinzeit und Stypven-Cephalin-Gerinnungszeit. Der Faktor-VII-Aktivitätstest kann unterschiedlich stark vermindert sein und Gewebethrombo-plastine verschiedener Herkunft sollten in diesem Test verwendet werden. Bei Fällen mit klassischem Mangel wird keine sichere Diskrepanz bei Verwendung verschiedener Thromboplastine beobachtet. Ein immunologischer Test ist notwendig, wenn eine Diskrepanz von mehr als 15% bei einem Faktor-VII-Aktivitätsspiegel von 40-60% der Norm erhalten wird und die Patienten vollständig asymptomatisch sind. Die Substitutionstherapie beruht auf der Verabreichung von Plasma, Prothrombinkomplex-Konzentraten und Faktor-VII-Kon-zentraten. Eine große Häufigkeit von Virushepatitis scheint die Verwendung der Faktor-VII-Konzentrate einzuschränken. Erworbene Faktor-VII-Defekte sind mit dem Mangel an anderen Faktoren des Prothrombinkom-plexes verbunden.
Collapse
|
15
|
Paolini R, Toffoli S, Poletti A, Casara D, Moschino P, Fabris F, Girolami A. Splenomegaly as the First Manifestation of Thyroid Cancer Metastases. TUMORI JOURNAL 2018; 83:779-82. [PMID: 9349322 DOI: 10.1177/030089169708300414] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We report the case of a 65-year-old man who developed a symptomatic splenomegaly due to spleen metastasis from thyroid follicular carcinoma. In 1982, at the age of 53, the patient had undergone a thyroid lobectomy for a cold node, followed one year later by a second intervention for a microfollicular adenoma. He was subsequently administered thyroid suppressive therapy with no further follow-up. The diagnosis of spleen metastases from thyroid cancer was first suspected on the basis of history, high serum thyroglobulin (Tg) levels, and the presence of pulmonary 99Tc uptake. The patient underwent a splenectomy, during which vast infiltration involving the diaphragm, spleen, stomach, colon and pancreas, was found. Histological and immunohistochemical results showed that the spleen and diaphragm metastases derived from thyroid follicular carcinoma. Radioiodine uptake by the pulmonary metastases confirmed the thyroid source. Retrospective re-evaluation of the thyroid tissue removed in 1983 revealed a histological pattern consistent with follicular carcinoma, which could not be unequivocally attributed to the widely or minimally invasive form. To our knowledge this is the first report of splenomegaly as the first manifestation of thyroid cancer metastases. In this paper cases of splenomegaly due to metastatic spread are reviewed and the management of the present case is discussed.
Collapse
|
16
|
Dittadi R, Meo S, Fabris F, Gasparini G, Contri D, Medici M, Gion M. Validation of Blood Collection Procedures for the Determination of Circulating Vascular Endothelial Growth Factor (VEGF) in Different Blood Compartments. Int J Biol Markers 2018. [DOI: 10.1177/172460080101600202] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Aims of the study. Studies on circulating VEGF have reported mixed results, possibly due to a lack of standardization of the pre-analytical phase. The aim of our investigation was to standardize the sampling procedure for the determination of VEGF in different blood fractions. Basic procedures. We evaluated various clotting times for obtaining serum in 30 subjects, as well as different procedures for the preparation of plasma Edinburgh anticoagulant mixture (EDTA, PGE1, theophylline) and CTAD. VEGF was also assayed in lysed whole blood. In vitro platelet activation was monitored by measuring the levels of PF4. VEGF and PF4 were measured using commercially available enzyme-linked immunoassays. Main findings. Clotting time increased the release of VEGF, which reached a plateau between 2 and 4 hours. The percent increase of VEGF at 2 hours ranged from 118% to 4515% (median 327%) compared to samples centrifuged within 10 min from withdrawal. VEGF was not different and PF4 was very low or undetectable in Edinburgh plasma and CTAD plasma, while it was significantly higher in sodium citrate plasma. VEGF in CTAD plasma was not correlated with platelet count or leukocytes. Serum VEGF did not correlate with the leukocyte number, but it correlated significantly with the platelet count. Principal conclusions. The procedures for sample collection described above are highly standardized and easy to perform in a routine setting. We therefore suggest systematic evaluation of VEGF in CTAD plasma, in serum (clotting for 2 hours at room temperature) and in whole blood, until prospective controlled clinical studies will have clarified in which blood compartment(s) VEGF provides clinically relevant information.
Collapse
|
17
|
Panzavolta C, Benvegnù L, Aghi A, Biolo M, Giannini S, Noale M, Tripepi G, Plebani M, Veronese N, Messa P, Rossini M, Gallieni M, Sella S, Fabris F, Manzato E, Previato L, Bertocco S, Zambon A, Fusaro M, Zambon S. Statin therapy reduces phospate levels in dialysis patients: Results from the epidemiological vitamin K Italian study (VIKI study). Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
18
|
Palese A, Ambrosi E, Fabris F, Guarnier A, Barelli P, Zambiasi P, Allegrini E, Bazoli L, Casson P, Marin M, Padovan M, Picogna M, Taddia P, Salmaso D, Chiari P, Marognolli O, Canzan F, Saiani L. Nursing care as a predictor of phlebitis related to insertion of a peripheral venous cannula in emergency departments: findings from a prospective study. J Hosp Infect 2016; 92:280-6. [DOI: 10.1016/j.jhin.2015.10.021] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2015] [Accepted: 10/19/2015] [Indexed: 11/15/2022]
|
19
|
Da Pian M, De Lucchi O, Strukul G, Fabris F, Scarso A. Cation templated improved synthesis of pillar[6]arenes. RSC Adv 2016. [DOI: 10.1039/c6ra07164c] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Improved high yield syntheses of the larger pillar[6]arenes (P[6]) bearing different alkoxy substituents through cation templated syntheses using a series of small organic and organometallic cations is reported.
Collapse
|
20
|
Girolami A, Bertozzi I, de Marinis GB, Bonamigo E, Fabris F. Activated FVII levels in factor VII Padua (Arg304Gln) coagulation disorder and in true factor VII deficiency: a study in homozygotes and heterozygotes. Hematology 2013; 16:308-12. [DOI: 10.1179/102453311x13085644680069] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
|
21
|
Foresta C, Strapazzon G, De Toni L, Fabris F, Grego F, Gerosa G, Vettore S, Garolla A. Platelets express and release osteocalcin and co-localize in human calcified atherosclerotic plaques. J Thromb Haemost 2013; 11:357-65. [PMID: 23206207 DOI: 10.1111/jth.12088] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND Although vascular-calcification mechanisms are only partially understood, the role of circulating calcifying cells and non-collagenous bone matrix proteins in the bone-vascular axis is emerging. In spite of the fact that platelets represent a cellular interface between hemostasis, inflammation and atherosclerosis, and have a myeloid precursor, a possible involvement in the modulation of vascular calcification has rarely been investigated. We investigated if osteocalcin (OC) is released by platelets and described OC expression in patients with carotid artery occlusive disease. METHODS Expression and release of OC were determined by Western blot, immunofluorescence, fluorescence-activated cell sorting (FACS) and ELISA in human resting and activated platelets and megakaryocytes. Co-localization of platelet aggregates, macrophages, OC and calcifications was studied in carotid endarterectomy specimens and normal tissues. RESULTS Human platelets expressed OC and co-localized with CD63 in δ-granules. Upon activation with an endogenous mechanism, platelets released OC in the extracellular medium. Expression of OC in megakaryocytes suggested lineage specificity. The OC count in circulating platelets and the released amount were significantly higher in patients with carotid artery occlusive disease than in healthy controls (P < 0.0001) in spite of similar serum levels. In atherosclerotic plaques, OC strongly overlapped with CD41+ platelets in the early stage of calcification, but this was not seen in normal tissues. CD68+OC+ cells were present at the periphery of the calcified zone. CONCLUSIONS Given the active role played by platelets in the atherosclerotic process, the involvement of OC release from platelets in atherosclerotic lesions and the impact of genetic and cardiovascular risk factors in mediating bone-marrow preconditioning should be investigated further.
Collapse
|
22
|
Marchini C, Fornasier A, Fabris F, Lo Cascio C, Marsala SZ. P4.14 Segmental analysis of orthodromic sensitive conduction velocity in distal tracts of tibial nerve with superficial electrodes derivation: normative data. Clin Neurophysiol 2011. [DOI: 10.1016/s1388-2457(11)60253-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
23
|
Ferrario E, Molaschi M, Cappa G, Seccia L, Villata E, Fabris F. Nutritional patterns in elderly patients with dementia of Alzheimer type. Arch Gerontol Geriatr 2009; 22 Suppl 1:23-7. [PMID: 18653002 DOI: 10.1016/0167-4943(96)86907-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Body weight and some nutritional serum parameters (albumin, urea nitrogen, creatinine, glycemia, hemoglobin, total cholesterol, triglycerides, potassium) were analyzed in 44 subjects aged over 60 in order to evaluate weight loss and its possible link with the progression of dementia. Patients were consecutively admitted to our Day Hospital with the complaint of psychogeriatric symptoms. They all were living at home, no one presented risk factors for malnutrition and their cognitive impairment did not exceed the 4th degree of GDS (Global Deterioration Scale). Subjects were divided into two groups on the basis of diagnosis at discharge: (i) Possible or probable dementia of Alzheimer type (30 subjects, mean age 72.1 +/- 5.9 years), (ii) Age-associated memory impairment (14 subjects, mean age 73.6 +/- 6.2 years). One year later, a second control of body weight and nutritional parameters was performed. Differences between these latter measures versus the initial values were not significant when analyzed in the total group of demented patients or in the subgroups with different degree of cognitive impairment and physical activity. A possible hypothesis to explain the absence of differences among groups is that the caregivers were very carefully looking after all the patients examined.
Collapse
|
24
|
Paternoster DM, Cester M, Memmo A, Scandellari R, Fabris F, Girolami A. The management of feto-maternal alloimmune thrombocytopenia: Report of three cases. J Matern Fetal Neonatal Med 2009; 19:517-20. [PMID: 16966118 DOI: 10.1080/14767050600746563] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
We report herein three cases of severe fetal thrombocytopenia due to anti-human platelet antigen (HPA)- 1a maternal antibodies. The first and the third cases were diagnosed on the basis of previously affected siblings and treated successfully by maternal intravenous human immunoglobulins and corticosteroids. In the second case an unexpected neonatal thrombocytopenia was found after birth without previously affected siblings and treated subsequently with intravenous immunoglobulins. Our experience supports a switch from an invasive management, including early FBS (fetal blood sampling) and platelet transfusions, to a more cautious approach. Also in severe HPA-1a alloimmunization and in 'high risk' fetuses, prenatal maternal treatment could be performed, without previous FBS, only on the basis of a risk score defined by sibling history and parents' genotypes.
Collapse
|
25
|
Vettore S, Scandellari R, Moro S, Lombardi AM, Scapin M, Randi ML, Fabris F. Novel point mutation in a leucine-rich repeat of the GPIb chain of the platelet von Willebrand factor receptor, GPIb/IX/V, resulting in an inherited dominant form of Bernard-Soulier syndrome affecting two unrelated families: the N41H variant. Haematologica 2008; 93:1743-7. [DOI: 10.3324/haematol.12830] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|